{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T16:14:30Z","timestamp":1793463270799,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.ijantimicag.2022.106590","type":"journal-article","created":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T21:00:36Z","timestamp":1649797236000},"page":"106590","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Systemic antifungal therapy for oesophageal candidiasis \u2013 systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"59","author":[{"given":"Heyam Atamna","family":"Mwassi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3181-9791","authenticated-orcid":false,"given":"Dafna","family":"Yahav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gida","family":"Ayada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sher","family":"Matsri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ili","family":"Margalit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liat","family":"Shargian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihad","family":"Bishara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa","family":"Atamna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/j.ijantimicag.2022.106590_bib0001","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1093\/clinids\/21.Supplement_1.S99","article-title":"Opportunistic candidal infections in patients infected with human immunodeficiency virus: prevention issues and priorities","volume":"21","author":"Reef","year":"1995","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106590_bib0002","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1086\/516315","article-title":"Oropharyngeal and esophageal candidiasis in immunocompromised patients: treatment issues","volume":"26","author":"Darouiche","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106590_bib0003","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1002\/cncr.23466","article-title":"The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy","volume":"112","author":"Hachem","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.ijantimicag.2022.106590_bib0004","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1128\/JCM.01283-12","article-title":"Species identification and antifungal susceptibility testing of candida bloodstream isolates from population-based surveillance studies in two U.S. cities from 2008 to 2011","volume":"50","author":"Lockhart","year":"2012","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2022.106590_bib0005","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/1469-0691.12440","volume":"20","author":"Orasch","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2022.106590_bib0006","doi-asserted-by":"crossref","first-page":"ofab471","DOI":"10.1093\/ofid\/ofab471","article-title":"Trends of the epidemiology of candidemia in Switzerland: a 15-year FUNGINOS survey","volume":"8","author":"Adam","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106590_bib0007","first-page":"1","article-title":"Population-based active surveillance for culture-confirmed candidemia \u2013 four sites, United States, 2012\u20132016","volume":"68","author":"Toda","year":"2019","journal-title":"Morb Mortal Wkly Rep Surveill Summ"},{"key":"10.1016\/j.ijantimicag.2022.106590_bib0008","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1111\/j.1572-0241.2003.07626.x","article-title":"Prevalence of esophageal candidiasis among patients treated with inhaled fluticasone propionate","volume":"98","author":"Kanda","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ijantimicag.2022.106590_bib0009","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1086\/514653","article-title":"Oropharyngeal candidiasis as a marker for esophageal candidiasis in patients with cancer","volume":"27","author":"Samonis","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106590_bib0010","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1001\/archinte.1991.00400080067012","article-title":"The causes of esophageal symptoms in human immunodeficiency virus infection. A prospective study of 110 patients","volume":"151","author":"Bonacini","year":"1991","journal-title":"Arch Intern Med"},{"issue":"Suppl. 7","key":"10.1016\/j.ijantimicag.2022.106590_bib0011","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/1469-0691.12042","article-title":"ESCMID guideline for the diagnosis and management of candida diseases 2012: patients with HIV infection or AIDS","volume":"18","author":"Lortholary","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2022.106590_bib0012","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1086\/596757","article-title":"Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America","volume":"48","author":"Pappas","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"Suppl. 7","key":"10.1016\/j.ijantimicag.2022.106590_bib0013","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/1469-0691.12041","article-title":"ESCMID guideline for the diagnosis and management of candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT)","volume":"18","author":"Ullmann","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2022.106590_bib0014","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2147\/TCRM.S882","article-title":"Anidulafungin in the treatment of invasive fungal infections","volume":"4","author":"Sabol","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.ijantimicag.2022.106590_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14787210.2021.1922078","article-title":"Efficacy and acceptability of different anti-fungal interventions in oropharyngeal or esophageal candidiasis in HIV co-infected adults: a pilot network meta-analysis","volume":"19","author":"Zeng","year":"2021","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.ijantimicag.2022.106590_bib0016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"10.1016\/j.ijantimicag.2022.106590_bib0017","unstructured":"Ketoconazole (systemic): Drug information \u2013 UpToDate. Available at: https:\/\/www-uptodate-com.beilinson-ez.medlcp.tau.ac.il\/contents\/ketoconazole-systemic-drug-information?search=ketoconazole&source=panel_search_result&selectedTitle=1\u223c146&usage_type=panel&display_rank=1 [accessed 29 August 2021]."},{"key":"10.1016\/j.ijantimicag.2022.106590_bib0018","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane handbook for systematic reviews of interventions. Oxford: Cochrane Collaboration. Available at: https:\/\/training.cochrane.org\/handbook [accessed 29 August 2021]."},{"key":"10.1016\/j.ijantimicag.2022.106590_bib0019","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.ijantimicag.2022.106590_bib0020","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1128\/AAC.04586-14","article-title":"A phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasis","volume":"59","author":"Viljoen","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106590_bib0021","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3109\/00365549509047076","article-title":"Fluconazole compared with itraconazole in the treatment of esophageal candidiasis in AIDS patients: a double-blind, randomized, controlled clinical study","volume":"27","author":"Barbaro","year":"1995","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106590_bib0022","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1053\/gast.1996.v111.pm8898629","article-title":"Fluconazole vs. itraconazole for candida esophagitis in acquired immunodeficiency syndrome. Candida esophagitis","volume":"111","author":"Barbaro","year":"1996","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ijantimicag.2022.106590_bib0023","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1378\/chest.110.6.1507","article-title":"Fluconazole vs. itraconazole-flucytosine association in the treatment of esophageal candidiasis in AIDS patients. A double-blind, multicenter placebo-controlled study. The Candida Esophagitis Multicenter Italian Study (CEMIS) Group","volume":"110","author":"Barbaro","year":"1996","journal-title":"Chest"},{"key":"10.1016\/j.ijantimicag.2022.106590_bib0024","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1086\/514028","article-title":"A randomized, double-blind comparison of itraconazole oral solution and fluconazole tablets in the treatment of esophageal candidiasis","volume":"176","author":"Wilcox","year":"1997","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106590_bib0025","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1086\/322653","article-title":"A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients","volume":"33","author":"Ally","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106590_bib0026","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1086\/423377","article-title":"A randomized, double-blind, parallel-group, dose\u2013response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients","volume":"39","author":"de Wet","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106590_bib0027","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/j.1365-2036.2005.02427.x","article-title":"A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis","volume":"21","author":"de Wet","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ijantimicag.2022.106590_bib0028","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0002-9343(02)01191-9","article-title":"A randomized double-blind study of caspofungin vs. fluconazole for the treatment of esophageal candidiasis","volume":"113","author":"Villanueva","year":"2002","journal-title":"Am J Med"},{"key":"10.1016\/j.ijantimicag.2022.106590_bib0029","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1086\/423378","article-title":"A randomized, double-blind trial of anidulafungin vs. fluconazole for the treatment of esophageal candidiasis","volume":"39","author":"Krause","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106590_bib0030","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1086\/323401","article-title":"A randomized double-blind study of caspofungin vs. amphotericin for the treatment of candidal esophagitis","volume":"33","author":"Villanueva","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106590_bib0031","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1128\/AAC.46.2.451-457.2002","article-title":"Randomized, double-blind, multicenter study of caspofungin vs. amphotericin B for treatment of oropharyngeal and esophageal candidiases","volume":"46","author":"Arathoon","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106590_bib0032","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s10096-012-1754-z","article-title":"A double-blind comparative study of the safety and efficacy of caspofungin vs. micafungin in the treatment of candidiasis and aspergillosis","volume":"32","author":"Kohno","year":"2013","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106590_bib0033","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1159\/000239459","article-title":"Fluconazole vs. amphotericin B in the treatment of esophageal candidiasis in cancer patients","volume":"42","author":"Lake","year":"1996","journal-title":"Chemotherapy"},{"key":"10.1016\/j.ijantimicag.2022.106590_bib0034","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. Available at: https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/AdultandAdolescentGL.pdf [accessed 9 May 2022]."},{"key":"10.1016\/j.ijantimicag.2022.106590_bib0035","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106590_bib0036","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1128\/CMR.00046-13","article-title":"Tissue penetration of antifungal agents","volume":"27","author":"Felton","year":"2014","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2022.106590_bib0037","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1128\/AAC.45.2.471-479.2001","article-title":"Dosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis","volume":"45","author":"Petraitis","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106590_bib0038","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1086\/505204","article-title":"Anidulafungin: a novel echinocandin","volume":"43","author":"Vazquez","year":"2006","journal-title":"Clin Infect Dis"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857922000942?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857922000942?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:42:37Z","timestamp":1760377357000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857922000942"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S0924857922000942"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2022.106590","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic antifungal therapy for oesophageal candidiasis \u2013 systematic review and meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2022.106590","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106590"}}